An observational study in Toxic Alcohol Poisoning, sponsored by Oslo University Hospital. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Oslo University Hospital · Observational
The project is a prospective observation study of patients with suspected or confirmed toxic alcohol poisoning treated with fomepizole and continuous renal replacement therapy (CRRT)
209 studies on the registry are indexed under Poisoning; 26 are open to participants now.
This study's enrollment of 11 is below the median of 121 across 94 observational studies indexed under Poisoning.
Browse Poisoning studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Toxic alcohol poisoning treated with fomepizole and CRRT.
Exclusion Criteria:
Measure minimum plasma concentration of fomepizole
Plasma samples will be obtained up to every hour and before fomepizole is given
Time frame: through study completion, up to 72 hours
Continuous renal replacement therapy (CRRT) clearance of fomepizole
Plasma and dialysat samples will be obtained up to every hour
Time frame: through study completion, up to 72 hours
Determine saturation/sieving coefficient of fomepizole
Plasma and dialysat samples will be obtained up to every hour
Time frame: through study completion, up to 72 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital